![](/images/graphics-bg.png)
Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer : Data from the TROG 96.01 Trial
المؤلفون المشاركون
Spry, Nigel A.
Lamb, David S.
Wynne, Chris
Atkinson, Chris
Denham, James W.
North, John
Matthews, John
Christie, David
Turner, Sandra
Steigler, Allison
Joseph, David
Tai, Keen-Hun
المصدر
العدد
المجلد 2012، العدد 2012 (31 ديسمبر/كانون الأول 2012)، ص ص. 1-11، 11ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-12-24
دولة النشر
مصر
عدد الصفحات
11
التخصصات الرئيسية
الملخص EN
Purpose.
Survival following biochemical failure is highly variable.
Using a randomized trial dataset, we sought to define a risk stratification scheme in men with locally advanced prostate cancer (LAPC).
Methods.
The TROG 96.01 trial randomized 802 men with LAPC to radiation ± neoadjuvant androgen suppression therapy (AST) between 1996 and 2000.
Ten-year follow-up data was used to develop three-tier post-biochemical failure risk stratification schemes based on cutpoints of time to biochemical failure (TTBF) and PSA doubling time (PSADT).
Schemes were evaluated in univariable, competing risk models for prostate cancer-specific mortality.
The performance was assessed by c-indices and internally validated by the simple bootstrap method.
Performance rankings were compared in sensitivity analyses using multivariable models and variations in PSADT calculation.
Results.
485 men developed biochemical failure.
c-indices ranged between 0.630 and 0.730.
The most discriminatory scheme had a high risk category defined by PSADT < 4 months or TTBF < 1 year and low risk category by PSADT > 9 months or TTBF > 3 years.
Conclusion.
TTBF and PSADT can be combined to define risk stratification schemes after biochemical failure in men with LAPC treated with short-term AST and radiotherapy.
External validation, particularly in long-term AST and radiotherapy datasets, is necessary.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Steigler, Allison& Denham, James W.& Lamb, David S.& Spry, Nigel A.& Joseph, David& Matthews, John…[et al.]. 2012. Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer : Data from the TROG 96.01 Trial. Prostate Cancer،Vol. 2012, no. 2012, pp.1-11.
https://search.emarefa.net/detail/BIM-500228
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Steigler, Allison…[et al.]. Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer : Data from the TROG 96.01 Trial. Prostate Cancer No. 2012 (2012), pp.1-11.
https://search.emarefa.net/detail/BIM-500228
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Steigler, Allison& Denham, James W.& Lamb, David S.& Spry, Nigel A.& Joseph, David& Matthews, John…[et al.]. Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer : Data from the TROG 96.01 Trial. Prostate Cancer. 2012. Vol. 2012, no. 2012, pp.1-11.
https://search.emarefa.net/detail/BIM-500228
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-500228
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)